Patent ID: 8758754

Claim:
A method of treatment of a disease of the peripheral (PNS) and/or central (CNS) nervous system comprising administering to a subject in need of such treatment an effective amount of an isolated protein comprising at least one antigen binding site which specifically binds to the human NogoA polypeptide (SEQ ID NO: 2) or human NiG (SEQ ID NO: 3), said antigen binding site comprising: in sequence the hypervariable regions CDR-H1, CDR-H2, and CDR-H3, wherein the hypervariable regions are CDR-H1-6A3 (SEQ ID NO: 8), CDR-H2-6A3 (SEQ ID NO: 9) and CDR-H3-6A3 (SEQ ID NO: 10), respectively; and in sequence the hypervariable regions CDR-L1, CDR-L2, and CDR-L3, wherein the hypervariable regions are CDR-L1-6A3 (SEQ ID NO: 11), CDR-L2-6A3 (SEQ ID NO: 12) and CDR-L3-6A3 (SEQ ID NO: 13), respectively.